ClinicalTrials.gg
TerminatedNCT03255798GCF-041Updated Sep 9, 2022

A Prospective Evaluation of Glaucoma Subjects Treated With Two Second Generation iStents and One iStent Supra

An interventional study of G2 and G3 in Glaucoma, Open-Angle, sponsored by Glaukos Corporation. Terminated at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-09.

Sponsored by Glaukos Corporation · Not applicable, Interventional, and Treatment

Why this study was terminated
Business decision

From the registry’s dates

  • Primary completion was Jun 2019, 7 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 43 studies in Glaucoma, Open-Angle by Glaukos Corporation — 7 open to participants now, 10 under way, 2 of them phase 3. Glaucoma, Open-Angle · Glaukos Corporation.

Enrollment
37th of 38
7 · median 111
Started
2017
the only one that year
No phase
15 of 43
none open now
Registered
26th of 43
by date

Among the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation, this one is the 37th largest by enrollment of the 38 interventional ones that give a count, is the only one that started in 2017, is one of 15 with no phase, and was the 26th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

7 of the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Glaucoma, Open-Angle by Glaukos Corporation, or all of them as a file.
02

Study summary

Prospective Evaluation of Open-Angle Glaucoma Subjects treated with two second generation iStents and one iStent Supra

Read the detailed description

Prospective Evaluation of Mild to Moderate Open-Angle Glaucoma Subjects treated with Two Second Generation Microbypass Stents and One Suprachoroidal Stent

03

Conditions studied

  • Glaucoma, Open-Angle

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Phakic or pseudophakic subjects with posterior chamber IOLs Primary open-angle glaucoma or pseudoexfoliative glaucoma diagnosis Subject on two ocular hypotensive medications Medicated screening IOP greater than or equal to 18 mm Hg and less than or equal to 30 mm Hg Visual field or optic nerve defect characteristic of glaucoma Normal iridocorneal angle anatomy Absence of peripheral anterior synechiae Mean diurnal IOP at baseline between 21 and 45 mm Hg

Exclusion criteria

Exclusion Criteria:

  • Subjects with anterior chamber IOLs Prior SLT or stent implantation in study eye Traumatic, uveitic, or neovascular glaucoma Fellow eye BCVA worse than 20/200
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Other
    G2 and G3 implantation

    Two iStent inject stents and one iStent Supra stent

    Device: G2 and G3

Interventions

  • DeviceG2 and G3

    Two iStent inject devices and one iStent supra device

06

What researchers measure

Primary outcomes

  1. 20% IOP reduction

    IOP reduction observed compared to baseline IOP, measured by Goldmann tonometry in mm Hg

    Time frame: Month 12

Secondary outcomes

  1. IOP less than or equal to 18 mm Hg

    IOP compared to baseline IOP, measured by Goldmann tonometry in mm Hg

    Time frame: Month 12

07

Study locations

1 site
  • Prof. Dr. med. Carl Erb
    Berlin, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Jun 2019, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2017
First posted
Aug 21, 2017
StartActual
Aug 1, 2017
Primary completionActual
Jun 6, 2019
CompletionActual
Jun 6, 2019
Last update
Sep 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03255798
Responsible party
Sponsor
First posted
Aug 21, 2017
Start date
Aug 1, 2017
Primary completion
Jun 6, 2019
Completion
Jun 6, 2019
Last update
Sep 9, 2022

Study contacts

Kerry Stephens, OD
study chair · Glaukos Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion